MBS303, a Novel 2:1 CD20×CD3 Bispecific Antibody,

mbs303MBS303MSC303 (MBS303 as the intravenous formulation, MSC303 as the subcutaneous formulation) is an innovative CD20CD3 T-cell engager. MBS303 has initiated clinical trialsMBS303 is a CD20×CD3 T-cell-engaging bispecific antibody that has a novel 2:1 (CD20:CD3) confuration to kill malnant B cells. This dose-escalation phase Ⅰ trial evaluated the safety